Economy

Nabriva Therapeutics AG (NBRV) Receiving Somewhat Favorable News Coverage, Study Finds

For every buyer, there needs to be someone who sold them the shares they bought, just as there must be a buyer in order for a seller to get rid of his or her shares.

Nabriva Therapeutics AG, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans.

A number of other analysts also recently issued reports on the company.

Nabriva Therapeutics plc (NBRV) surprised the stock market in its last reported earnings when it earned -$0.54 a piece versus the consensus-estimated -$0.6.

Nabriva Therapeutics plc (NBRV) saw -14.35 million in free cash flow last quarter, representing a quarterly net change in cash of -5.47 million.

Needham now has a $18.0 target on the $302.55 million market cap company or 117.92 % upside potential. The share price has moved backward from its 20 days moving average, trading at a distance of -3.29% and stays -12.7% away from its 50 days moving average. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Nabriva Therapeutics AG in a research note on Friday, June 23rd. The rating was maintained by Wedbush on Wednesday, February 1 with "Outperform".

Analyst recommendations as reported on FINVIZ are rated on a 1 to 5 scale.

Investors wait Nabriva Therapeutics plc - Ordinary Shares (NASDAQ:NBRV) to report on November, 15. its quarterly earnings Wall Street analysts expect $-0.56 EPS, up $0.10 or 15.15 % from last year's $-0.66 same quarter earnings.

Several equities research analysts recently commented on NBRV shares. Almanack Investment Partners. has an ownership of 907,183 stocks of the biotechnology firms shares valued $1,633,000 following purchasing an extra 751,366 shares through out the previous quarter, Wellington Management Group LLP upped its stake in Nabriva Therapeutics AG by 9.9% through out the 1st period. ValuEngine raised shares of Nabriva Therapeutics AG from a "sell" rating to a "hold" rating in a research note on Saturday, June 24th. As of quarter end Hillhouse Capital Management, Ltd. had sold 500 shares trimming its position 0.1%. The corporation has a consensus rating of "Buy" and an consensus price target of $19.13. Research Firm Zacks boosted Nabriva Therapeutics AG from a "hold" recommendation to a "buy" recommendation and fixed a $12.00 PT for the company in a study note published on early Thur, Aug 10th.

Nabriva Therapeutics plc has a consensus outperform rating from 7 Wall Street analysts, and the number of shares now sold short amount to at least 0.41% of shares outstanding. The company now has an average rating of Buy and a consensus price target of $19.13. If you are reading this piece on another site, it was copied illegally and republished in violation of USA and worldwide copyright laws. The correct version of this piece of content can be accessed at https://www.truebluetribune.com/2017/09/21/nabriva-therapeutics-ag-nbrv-given-media-sentiment-rating-of-0-11.html. The stock was sold at an average price of $8.56, for a total value of $313,364.48. Following the completion of the sale, the insider now directly owns 2,591,396 shares in the company, valued at approximately $28,401,700.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The rating was initiated by Needham with "Buy" on Monday, October 12. For the quarter, shares have been noted at -26.36%. The disclosure for this purchase can be found here.

The counter witnessed a trading volume of 2.24 million shares versus an average volume of 1.82 million shares during last trading session. This continues to be an interesting story, and we look forward to updating it again soon on Nabriva Therapeutics plc.



Like this

loading...
loading...

Latest


22 September 2017
Teva Pharmaceutical Industries Limited (TEVA) Cut to "Strong Sell" at BidaskClub
Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. Teva Pharmaceutical Industries Limited (NYSE: TEVA ) last issued its earnings results on Thursday, August 3rd.

22 September 2017
North Korea will be "destroyed" if threats, 'reckless behavior' continues
About 25 million people live in North Korea. "We wanted to be responsible and go through all diplomatic means to get their attention first", Haley said.

22 September 2017
Leidos Holdings, Inc. (LDOS) Holdings Lifted by FIL Ltd
Finally, DekaBank Deutsche Girozentrale purchased a new stake in shares of Leidos Holdings in the 1st quarter valued at $247,000. TRADEMARK VIOLATION WARNING: This report was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal.

22 September 2017
Iran's Rowhani condemns 'ignorant, absurd and hateful' Trump at UN
Trump has long railed against the deal President Barack Obama struck with Iran to curb the nation's nuclear ambitions. That's what President Trump said yesterday when asked whether he had decided what to do about the Iran nuclear deal .

22 September 2017
Magellan Midstream Partners LP (NYSE:MMP) Shares Sold by Payden & Rygel
The pipeline company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $0.03. Salient Trust Company Lta decreased Magellan Midstream Prtnrs Lp (MMP) stake by 56.13% reported in 2017Q2 SEC filing.

22 September 2017
Myanmar's VP: Government 'Deeply Concerned' About Rakhine
What is little known is that the great majority of the Muslim population made a decision to remain in their villages, he stated. U Henry Van Thio reiterated de facto leader Aung San Suu Kyi's pledge Tuesday to allow refugees to return home.

22 September 2017
Record number of states punishing human rights activism
Vice President Mike Pence referred to and criticized the Council for keeping countries that violate human rights as members. Some have featured in the annual report on reprisals almost every year since it was instituted in 2010.

22 September 2017
FG reaches agreement with SSANU, NASU to suspend strike
The national president of the Joint Action Committee, Sam Ugwoke, made the announcement at a media briefing on Thursday in Abuja. This post was syndicated from The Guardian Nigeria Newspaper - Nigeria and World News.

22 September 2017
Micron Technology, Inc. (MU) Receives "Hold" Rating from KeyCorp
Another trade for 3,300 shares valued at $345,355 was sold by Ryan Edward A. 87 funds opened positions while 181 raised stakes. Empire Life Investments Inc. purchased a new stake in Micron Technology during the 1st quarter worth $8,813,000. (NASDAQ:MU).

22 September 2017
Donaldson Company Inc (DCI) Needle Moving 0.42%
Following the completion of the sale, the director now owns 495,572 shares of the company's stock, valued at $33,892,169.08. Healy now forecasts that the company will earn $0.96 per share for the quarter, up from their previous forecast of $0.91.